← Back to Search

Cell Therapy

BMAC/PRP Injection Group for Osteoarthritis (BMAC Trial)

N/A
Waitlist Available
Led By Ivan Wong, MD
Research Sponsored by Nova Scotia Health Authority
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

BMAC Trial Summary

The purpose of this study is to evaluate the effect of combined Bone marrow aspirate concentrate (BMAC) and Platelet Rich Plasma (PRP) action after a single hip intraarticular injection to young symptomatic patients with primary radiologic stage of hip OA (Kellgren-Lawrence grade I or II) compared to a control local anesthetic with cortisone injection group of patients. The hypothesis is that the patients with hip OA will benefit more and for longer from OA symptoms in the BMAC and PRP group rather than in the group of local anaesthetic and cortisone. Furthermore, this study could be valuable in determining the safety and effectiveness of the BMAC and PRP combined injection for early low grade hip OA in young active patients who are neither good candidates for total hip replacement nor preservative hip surgery.

Eligible Conditions
  • Osteoarthritis

BMAC Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Functional Benefit and Pain Level Changes using iHOT33 Questionnaire
Secondary outcome measures
Burden of Disease and Quality of Life Changes using the Veterans RAND 12 Item Health Survey (VR-12)
Functional Benefit and Pain level Changes using the The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Functional Benefit and Pain level Changes using the modified Harris Hip Score (HHS)
+1 more

Side effects data

From 2018 Phase 4 trial • 1670 Patients • NCT02261727
32%
COPD Exacerbation - not hospitalised
16%
COPD Exacerbation - Hospitalised
7%
Upper Respiratory Tract Infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Low-dose Theophylline Arm
Theophylline and Prednisone Arm

BMAC Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: BMAC/PRP Injection GroupExperimental Treatment1 Intervention
This group will receive an injection of BMAC/PRP for treatment of OA
Group II: Cortisone Injection GroupActive Control1 Intervention
This group will receive an injection of cortisone for treatment of OA

Find a Location

Who is running the clinical trial?

Nova Scotia Health AuthorityLead Sponsor
262 Previous Clinical Trials
84,856 Total Patients Enrolled
11 Trials studying Osteoarthritis
631 Patients Enrolled for Osteoarthritis
Ivan Wong, MDPrincipal InvestigatorNova Scotia Health Authority
4 Previous Clinical Trials
204 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~1 spots leftby May 2025